---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-120092"
form_type: "8-K"
ticker: "TAOX"
cik: "0001571934"
company_name: "TAO Synergies Inc."
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:50:48.748889+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Synaptogenix raises $15M from existing investors in private placement of preferred stock and warrants

## Summary
- Gross proceeds of $15M from sale of Series B convertible preferred stock (initial conversion at $7.75/share) and warrants.
- Warrants to acquire up to 1,935,485 shares at $7.75; 5-year term; conversion price ~25% premium to prior close.
- Closing expected Nov 21, 2022; net proceeds for general corporate purposes.
- CEO cites strengthening balance sheet ahead of topline Phase 2 Alzheimer's trial results expected in December 2022.
- Preferred shares carry 7% annual dividend, redeemable in 15 monthly installments starting April 2023.

## SEC filing metadata
- accession: 0001104659-22-120092
- form_type: 8-K
- ticker: TAOX
- cik: 0001571934
- company_name: TAO Synergies Inc.
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1571934/000110465922120092/0001104659-22-120092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1571934/000110465922120092/tm2230905d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-120092
- JSON: https://secwatch.observer/filing/0001104659-22-120092.json
- Plain text: https://secwatch.observer/filing/0001104659-22-120092.txt

## Key facts
- Material Agreements
  TAO Synergies Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $15 million (effective 2022-11-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $15 million
  - Effective: 2022-11-17
  source text: On November 17, 2022, Synaptogenix, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 15,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 1,935,485 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a conversion price of $7.75 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 1,935,485 shares of Common Stock (the “Warrants”) (collectively, the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1571934/000110465922120092/0001104659-22-120092-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.